La FDA revisa la descripci ón de los efectos secundarios para la salud mental de los medicamentos para dejar de fumar Chantix (vareniclina) y Zyban (bupropión) para reflejar las conclusiones de estudio clínico
FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings
An FDA review found the side effects on mood, behavior, or thinking with the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) are lower than previously suspected. These risks still exist, but we believe the benefits of quitting smoking outweigh them. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2018 Category: Drugs & Pharmacology Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: La FDA actualiza la etiqueta del medicamento para dejar de fumar Chantix (vareniclina), para incluir la posible interacci ón con el alcohol, un riesgo poco común de sufrir convulsiones, y los estudios de efectos secundarios en el estado de ánimo, la conducta o el pensamiento
[3-9-2015] La Administraci ón de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) advierte que el medicamento de prescripción médica para dejar de fumar Chantix (vareniclina) puede alterar el modo en que las personas reaccionan al alcohol. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2018 Category: Drugs & Pharmacology Source Type: news
NIAAA Spectrum: Anti-Smoking Medication May Reduce Alcohol Craving
Varenicline, an anti-smoking medication, may reduce craving for alcohol in people who drink heavily and for people with alcohol use disorder (AUD) who are also depressed, according to two recent studies. The research, funded by NIAAA and led by Sherry McKee, Ph.D., Professor of Psychiatry at Yale School of Medicine, provides more evidence that varenicline may be a potential treatment for AUD. (Source: NIAAA News)
Source: NIAAA News - February 15, 2018 Category: Addiction Authors: Kimberly Source Type: news
FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events
[10-24-2011] The U.S. Food and Drug Administration (FDA) has reviewed the results from two FDA-sponsored epidemiological studies that evaluated the risk of neuropsychiatric adverse events associated with the smoking cessation drug Chantix (varenicline). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2018 Category: Drugs & Pharmacology Source Type: news
Varenicline Decreases Heavy Drinking in Male Smokers Varenicline Decreases Heavy Drinking in Male Smokers
Varenicline is FDA-approved as an agent to assist with smoking cessation. A new study suggests it may be useful in reducing heavy drinking in male smokers with comorbid alcohol use disorder.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - January 11, 2018 Category: Psychiatry Tags: Psychiatry News Source Type: news
Varenicline for Smoking Cessation Linked to Cardiac Events Varenicline for Smoking Cessation Linked to Cardiac Events
Observational results show increased risk for cardiovascular events in patients prescribed varenicline to stop smoking, although researchers say the benefit of smoking cessation may be worth the risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 2, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
Varenicline May Increase Cardiovascular Risk
(MedPage Today) -- Observational study found 34% higher rates of CV events after starting stop-smoking drug (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 21, 2017 Category: Primary Care Source Type: news
Stop-smoking drug increases users' risk of a heart attack
Researchers from the University of Toronto found varenicline, which is prescribed under the brand name Chantix, raises users' chances of being hospitalized due to a cardiovascular event. (Source: the Mail online | Health)
Source: the Mail online | Health - December 20, 2017 Category: Consumer Health News Source Type: news
Varenicline Use Tied to Elevated Risk for Cardiovascular Hospitalizations
The smoking cessation drug varenicline is associated with increased risk for cardiovascular hospitalizations, according to a self-controlled study in the American Journal of Respiratory... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 20, 2017 Category: Primary Care Source Type: news
Smoking cessation drug may increase risk of adverse cardiovascular event
(American Thoracic Society) Varenicline, one of the most commonly prescribed drugs for helping people quit smoking, may put them at higher risk for a cardiovascular event, according to new research published online in the American Journal of Respiratory and Critical Care Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2017 Category: International Medicine & Public Health Source Type: news
FDA Drug Safety Communication: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, or thinking
[03-09-2015] The U.S. Food and Drug Administration (FDA) is warning that the prescription smoking cessation medicine Chantix (varenicline) can change the way people react to alcohol. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news
Smoking study personalizes treatment
(Vanderbilt University Medical Center) A simple blood test is allowing Vanderbilt University Medical Center (VUMC) researchers to determine which patients should be prescribed varenicline (Chantix) to stop smoking and which patients could do just as well, and avoid side effects, by using a nicotine patch. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 20, 2017 Category: International Medicine & Public Health Source Type: news
Pfizer Recalls All Lots of Anti - Smoking Drug Chantix Due to Potential Carcinogen
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Preventive Medicine, News, Source Type: news
Varenicline Combo, Extension No Better for Quitting Smoking
Combining varenicline with nicotine patch, extending treatment from 12 to 24 weeks did not increase smoking cessation rates (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 12, 2017 Category: Respiratory Medicine Tags: Cardiology, Endocrinology, Family Medicine, Internal Medicine, Pharmacy, Psychiatry, Pulmonology, Journal, Source Type: news
